

High Potency Active Pharmaceutical Ingredients (HPAPI)-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/H1DFBDE6E5FMEN.html

Date: May 2018 Pages: 132 Price: US\$ 3,480.00 (Single User License) ID: H1DFBDE6E5FMEN

Abstracts

Report Summary

High Potency Active Pharmaceutical Ingredients (HPAPI)-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on High Potency Active Pharmaceutical Ingredients (HPAPI) industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of High Potency Active Pharmaceutical Ingredients (HPAPI) 2013-2017, and development forecast 2018-2023 Main market players of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA, with company and product introduction, position in the High Potency Active Pharmaceutical Ingredients (HPAPI) market Market status and development trend of High Potency Active Pharmaceutical Ingredients (HPAPI) by types and applications Cost and profit status of High Potency Active Pharmaceutical Ingredients (HPAPI), and marketing status Market growth drivers and challenges

The report segments the EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) market as:

EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue



and Growth Rate 2013-2023):

Europe Middle East Africa

EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Synthetic Biotech

EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Synthetic Biotech Oncology Hormonal Glaucoma Others

EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Players Segment Analysis (Company and Product introduction, High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume, Revenue, Price and Gross Margin):

Eli Lilly and Company Novartis International AG Bristol-Myers Squibb Company Roche Diagnostics Limited Sanofi Aventis Hospira, Inc. BASF AG Covidien Plc Boehringer Ingelheim GmbH Merck & Co., Inc. Sigma Aldrich Corporation Bayer AG

High Potency Active Pharmaceutical Ingredients (HPAPI)-EMEA Market Status and Trend Report 2013-2023



Carbogen Amcis AG Lonza Teva Pharmaceuticals Industries Ltd.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)

1.1 Definition of High Potency Active Pharmaceutical Ingredients (HPAPI) in This Report

1.2 Commercial Types of High Potency Active Pharmaceutical Ingredients (HPAPI)

- 1.2.1 Synthetic
- 1.2.2 Biotech

1.3 Downstream Application of High Potency Active Pharmaceutical Ingredients (HPAPI)

- 1.3.1 Synthetic
- 1.3.2 Biotech Oncology
- 1.3.3 Hormonal
- 1.3.4 Glaucoma
- 1.3.5 Others

1.4 Development History of High Potency Active Pharmaceutical Ingredients (HPAPI)

1.5 Market Status and Trend of High Potency Active Pharmaceutical Ingredients (HPAPI) 2013-2023

1.5.1 Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023

1.5.2 Regional High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific 2013-2017

2.2 Consumption Market of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Regions

2.2.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Regions

2.2.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Regions

2.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Regions

2.3.1 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in China 2013-2017



2.3.2 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Japan 2013-2017

2.3.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Korea 2013-2017

2.3.4 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in India 2013-2017

2.3.5 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Southeast Asia 2013-2017

2.3.6 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Australia 2013-2017

2.4 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific 2018-2023

2.4.1 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific 2018-2023

2.4.2 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients

(HPAPI) in Asia Pacific by Types

3.1.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in China
- 3.2.2 Market Status by Types in Japan
- 3.2.3 Market Status by Types in Korea
- 3.2.4 Market Status by Types in India
- 3.2.5 Market Status by Types in Southeast Asia
- 3.2.6 Market Status by Types in Australia

3.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Downstream Industry



4.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Major Countries

4.2.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in China

4.2.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Japan

4.2.3 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Korea

4.2.4 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in India

4.2.5 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Southeast Asia

4.2.6 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Australia

4.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)

5.1 Asia Pacific Economy Situation and Trend Overview

5.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Downstream Industry Situation and Trend Overview

CHAPTER 6 HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI) MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

6.1 Sales Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Major Players

6.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Asia Pacific by Major Players

6.3 Basic Information of High Potency Active Pharmaceutical Ingredients (HPAPI) by Major Players

6.3.1 Headquarters Location and Established Time of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players

6.3.2 Employees and Revenue Level of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News



6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Eli Lilly and Company

7.1.1 Company profile

7.1.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.1.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Eli Lilly and Company

7.2 Novartis International AG

7.2.1 Company profile

7.2.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.2.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Novartis International AG

7.3 Bristol-Myers Squibb Company

7.3.1 Company profile

7.3.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.3.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

7.4 Roche Diagnostics Limited

7.4.1 Company profile

7.4.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.4.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Roche Diagnostics Limited

7.5 Sanofi Aventis

7.5.1 Company profile

7.5.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.5.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sanofi Aventis

7.6 Hospira, Inc.

7.6.1 Company profile

7.6.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)



Product

7.6.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Hospira, Inc.

7.7 BASF AG

7.7.1 Company profile

7.7.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.7.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of BASF AG

7.8 Covidien Plc

7.8.1 Company profile

7.8.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.8.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Covidien Plc

7.9 Boehringer Ingelheim GmbH

7.9.1 Company profile

7.9.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.9.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH

7.10 Merck & Co., Inc.

7.10.1 Company profile

7.10.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.10.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.

7.11 Sigma Aldrich Corporation

7.11.1 Company profile

7.11.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.11.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sigma Aldrich Corporation

7.12 Bayer AG

7.12.1 Company profile

7.12.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.12.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bayer AG



7.13 Carbogen Amcis AG

7.13.1 Company profile

7.13.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.13.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Carbogen Amcis AG

7.14 Lonza

7.14.1 Company profile

7.14.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.14.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Lonza

7.15 Teva Pharmaceuticals Industries Ltd.

7.15.1 Company profile

7.15.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.15.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals Industries Ltd.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)

8.1 Industry Chain of High Potency Active Pharmaceutical Ingredients (HPAPI)

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)

9.1 Cost Structure Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)9.2 Raw Materials Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)

9.3 Labor Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)9.4 Manufacturing Expenses Analysis of High Potency Active PharmaceuticalIngredients (HPAPI)

CHAPTER 10 MARKETING STATUS ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)



- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: High Potency Active Pharmaceutical Ingredients (HPAPI)-EMEA Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/H1DFBDE6E5FMEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/H1DFBDE6E5FMEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



High Potency Active Pharmaceutical Ingredients (HPAPI)-EMEA Market Status and Trend Report 2013-2023